Invivyd, Inc. (IVVD): Total Liabilities
$35.34M
As of 2025-12-31
$37.80M
As of 2026-06-30
+9.1%
3-year compound annual growth
+22.0%
5-year compound annual growth
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $35.34M | -43.0% | 2026-03-05, Balance as of period end |
| 2024-12-31 | $61.98M | +19.8% | 2026-03-05, Balance as of period end |
| 2023-12-31 | $51.71M | +90.1% | 2025-03-20, Balance as of period end |
| 2022-12-31 | $27.20M | -56.2% | 2024-03-28, Balance as of period end |
| 2021-12-31 | $62.07M | +374.4% | 2023-03-23, Balance as of period end |
| 2020-12-31 | $13.08M | n/a | 2022-03-31, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| Invivyd, Inc. (IVVD) | 2025-12-31 | $35.34M | -43.0% |
| Protalix BioTherapeutics, Inc. (PLX) | 2025-12-31 | $34.12M | +12.9% |
| Champions Oncology, Inc. (CSBR) | 2026-04-30 | $22.92M | -19.8% |
| Fennec Pharmaceuticals Inc. (FENC) | 2025-12-31 | $35.08M | -31.0% |
| Vir Biotechnology, Inc. (VIR) | 2025-12-31 | $237.55M | -4.4% |
| Black Diamond Therapeutics, Inc. (BDTX) | 2025-12-31 | $30.80M | -21.7% |
| Editas Medicine, Inc. (EDIT) | 2025-12-31 | $159.25M | -23.2% |
| Voyager Therapeutics, Inc. (VYGR) | 2025-12-31 | $56.20M | -39.8% |
| Sangamo Therapeutics, Inc (SGMOQ) | 2025-12-31 | $74.01M | -6.2% |
Compare IVVD, PLX, CSBR, FENC side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗